In recent years a dramatic increase in knowledge of the biology of the lymphomas has been accompanied by the emergence of new treatments offering improvements in efficacy and reduction in toxicity. In this volume an internationally recognized group of experts review relevant aspects of the biology, diagnosis and management, with particular emphasis on the emerging data available for this disease.

This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.

A brand-new edition of the bestselling guide to hematologic malignancies. An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers. Following on the successful steps of the first edition, this Second Edition covers: various types of leukemias, lymphomas, and myelomas utilizing stem cell transplantation side-effects of various treatments future prospects for leukemia, lymphoma, and myeloma targeted therapies and history of the cancers information and support sources for patients

This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells. This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.

Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.

A guide to recent insights into the genetic and epigenetic parameters of cancer biology and pathology and emerging clinical applications The thoroughly updated second edition of The Biology and Treatment of Cancer, now titled Cancer: Prevention, Early Detection, Treatment and Recovery, goes beyond reviewing the fundamental properties of cancer biology and the relevant issues associated with treatment of the disease. The new edition contains coverage of additional "patient centric" topics and presents cancer biology with selection of topics, facts, and perspectives written in easy-to-understand terms. With contributions from noted experts, the book explores recent advances in the understanding of cancer including breakthroughs in the molecular and cellular basis of cancer and provides strategies for approaching cancer prevention, early detection, and treatment. The authors incorporate recent information on the genetic and epigenetic parameters of cancer biology and pathology with indications of emerging clinical applications. The text offers a unique guide to cancer prevention, early detection, treatment, and recovery for students, caregivers, and most importantly cancer patients. This significant book: Incorporates current insight into the genetic and epigenetic parameters of cancer biology and pathology and information on emerging clinical applications Contains contributions from leaders in cancer research, care, and clinical trials Offers an accessible guide to an accurate and balanced understanding of cancer and the cancer patient Focuses on the importance of cancer prevention, early detection, treatment, and survivorship Written for medical students, students of cancer biology, and caregivers and cancer patients, Cancer: Prevention, Early Detection, Treatment and Recovery offers an authoritative overview of the challenges and opportunities associated with cancer biology, cancer research, and the spectrum of clinical considerations.

This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included.

Written by over 50 internationally distinguished experts, 30 more than the first edition, and contains nine new chapters! Continuing in the esteemed tradition and heralded success of the first edition, Chronic Lymphoid Leukemias, Second Edition offers a full overview of chronic lymphocytic leukemia (CLL) from multiple perspectives-covering all major developments since the previous edition was published eight years ago. Chronicling the complete history and variations of CLL-type leukemia, the Second Edition reviews the origin, nature, and molecular differences between B-CLL and T-CLL/PLL leukemias analyzes core constituents of apoptosis and causes for dysregulation of programmed cell death (PCD) in B-CLL examines recent research on the role cytokines and regulatory molecules may play in cross-cell communication profiles commonly used vectors for somatic gene therapy, as well as the latest advances in genetic engineering and vector design and production utilizes up-to-the-minute techniques such as fluorescence in-situ hybridization (FISH) and comparative genomic hybridization (CGH) to detect genetic abnormalities and aberrations explores current measures of supportive care with splenectomy, cytokine proteins, and intravenous immunoglobulin applications identifies how to manage infectious and psychiatric complications in patients with CLL and much more! Provides contemporary results on the efficacy of nucleoside analog combinations such as ara-C with fludarabine and cladribine and on the emerging nucleosides nelarabine and clofarabine! Copiously supplemented with over 2500 literature references-1000 more than the first edition-Chronic Lymphoid Leukemias, Second Edition fulfills the reference needs of oncologists, hematologists, immunologists, pathologists, infectious disease specialists, internists, molecular biologists, and medical school students in these disciplines.

This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students.